Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aussan Laboratories Pty Ltd. is engaged in patent prosecution within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows a low volume of active matters, with 1 pending office action on record. This suggests a targeted strategy for their current intellectual property development in the biotech sector, potentially focusing on a key innovation or a specific market application.
The administrative footprint of the company's prosecution is limited to a distinct examiner and a distinct art unit. This concentration implies that the company's current technical claims are being evaluated by a specialized reviewer. PEEBLES, KATHERINE is identified as the busiest examiner for the company, currently handling 1 pending office action. Because this examiner is the only individual currently reviewing the company's pending work, the outcome of their immediate patenting goals is dependent on the specific standards and feedback of this individual, necessitating a focused legal approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEEBLES, KATHERINE | 1 | 35.6% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280170 | A COMPOSITION AND PROCESS FOR IMPROVING A PLANT'S ABILITY TO REDUCE ATMOSPHERIC CO2 | PEEBLES, KATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280170 | A COMPOSITION AND PROCESS FOR IMPROVING A PLANT'S ABILITY TO REDUCE ATMOSPHERIC CO2 | PEEBLES, KATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280170 | A COMPOSITION AND PROCESS FOR IMPROVING A PLANT'S ABILITY TO REDUCE ATMOSPHERIC CO2 | PEEBLES, KATHERINE | 1617 | §101§103§112DP | Final Rejection | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAussan Laboratories Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katherine Peebles has the most, with 1 of Aussan Laboratories Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
